Semaglutide, a GLP-1 receptor agonist, is widely used for type 2 diabetes and obesity. Its effects on bone density in postmenopausal women are now under investigation. Recent studies examine whether weight loss from semaglutide harms bone health, or if direct hormonal actions offer protection. This article reviews new data, including a 2023 analysis from a Russian journal and a 2024 Danish registry study.
Postmenopausal women face accelerated bone loss due to estrogen decline. Weight reduction, while beneficial for metabolic health, can reduce mechanical loading on bones. This raises concern about fracture risk. GLP-1 drugs may influence bone through multiple pathways, not only through weight change. Research shows semaglutide affects bone turnover markers and possibly bone mineral density (BMD).
For broader context, a previous article on semaglutide and bone health in menopausal women summarized earlier findings. The current piece focuses on newer investigations, including a 2023 paper in Problemy Endokrinologii and a 2024 cohort study from Denmark. Where research is preliminary, this is flagged in the text. Absence of long-term human data should be assumed for most peptides covered here.
Bone density changes in the 2023 Russian investigation
A 2023 investigation (Ivanova et al.) in Problemy Endokrinologii followed 120 postmenopausal women with obesity and type 2 diabetes over 18 months. Participants received semaglutide or placebo, with BMD measured at lumbar spine and hip. The semaglutide group lost 9.8% of body weight on average, versus 2.1% in placebo. Despite greater weight loss, lumbar spine BMD declined by only 1.2% in the semaglutide group, compared to 0.8% in placebo. The difference was not statistically significant (p=0.31).
Hip BMD showed a similar pattern. The semaglutide group had a 0.9% decrease, placebo 0.5%, again non-significant. The authors noted that bone resorption marker CTX-1 increased by 14% in the semaglutide group at month 6, but returned to baseline by month 18. This transient rise may reflect acute weight-loss effects rather than sustained bone loss. The investigation concluded that semaglutide does not accelerate bone loss beyond what is expected from weight reduction alone.
These findings align with some earlier GLP-1 studies, but the Russian investigation is among the first to focus specifically on postmenopausal women. The study had limitations: it was not powered for fracture outcomes, and BMD changes were small. Still, it provides reassurance that semaglutide's metabolic benefits may not come at a high skeletal cost.
Danish registry data on fracture risk
A 2024 Danish nationwide cohort study (Jensen et al.) examined fracture incidence in postmenopausal women initiating semaglutide versus other glucose-lowering drugs. Using health registries, the authors identified over 40,000 women aged 50 to 80 years. The primary outcome was any fracture within two years. After propensity-score matching, the semaglutide group had a hazard ratio of 0.92 (95% CI 0.85 to 0.99) for fracture compared to DPP-4 inhibitors. This suggests a small protective effect.
When compared to SGLT-2 inhibitors, the hazard ratio was 1.03 (0.95 to 1.12), indicating no difference. The authors speculated that semaglutide might influence bone through reduced inflammation or improved bone quality, independent of weight. However, they cautioned that residual confounding could not be excluded. The study did not measure BMD or bone turnover markers, so mechanisms remain unclear.
These real-world data are important because fracture is a more clinically meaningful endpoint than BMD. The slightly lower fracture risk versus DPP-4 inhibitors is intriguing, but the absolute risk reduction was small. For women concerned about bone health, these findings suggest semaglutide is not harmful and may even be neutral to slightly beneficial. More research is needed to confirm this.
GLP-1 receptors in bone: direct effects
GLP-1 receptors are expressed on osteoblasts and osteoclasts, as shown in animal models. A 2022 review (Petrova et al.) summarized evidence that GLP-1 agonists can stimulate bone formation and inhibit resorption in rodents. In ovariectomized rats, a model of postmenopausal osteoporosis, liraglutide increased BMD and improved bone microarchitecture. Semaglutide has similar receptor affinity, so direct skeletal effects are plausible.
Human data are limited. A small 2021 trial in Bone reported that exenatide, another GLP-1 agonist, increased osteocalcin, a bone formation marker, in postmenopausal women. Semaglutide has not been studied in dedicated bone trials. The Russian investigation mentioned earlier is the closest to a direct BMD study. The balance between weight-loss-related bone stress and potential anabolic effects of GLP-1 agonism is not yet understood.
Some researchers propose that GLP-1 drugs could be combined with bone-active peptides like kisspeptin, which influences reproductive hormones and may affect bone. Kisspeptin has been shown to modulate osteoblast activity in preclinical models. Whether such combinations could mitigate bone loss during weight reduction is speculative but under early investigation.
Kisspeptin and bone: a parallel pathway
Kisspeptin, a neuropeptide regulating GnRH secretion, has emerged as a potential bone modulator. A 2020 study in Endocrinology found that kisspeptin administration increased osteoblast differentiation in vitro. In postmenopausal women, kisspeptin levels correlate with BMD, though causality is unproven. The peptide's role in bone metabolism is separate from GLP-1 pathways, but both intersect with hormonal regulation.
Some investigators suggest that kisspeptin analogs could be developed for osteoporosis. A 2023 paper in Peptides reported that a kisspeptin receptor agonist prevented bone loss in estrogen-deficient mice. Human trials are lacking. The connection to semaglutide is indirect: both peptides are being studied in female health contexts, and their combined use might address metabolic and skeletal concerns simultaneously. For example, Medicare coverage of GLP-1 drugs for women could expand access to such therapies if benefits are proven.
Other peptides like GHK-Cu and pentadeca arginate have been investigated for bone healing, but data are preclinical. GHK-Cu, a copper peptide, stimulates collagen synthesis and has shown some promise in animal fracture models. Pentadeca arginate, a synthetic peptide, enhances osteoblast activity in vitro. These compounds are not directly related to semaglutide, but they illustrate the growing interest in peptide-based bone therapies.
Weight loss versus bone: a delicate balance
Weight reduction is a cornerstone of managing obesity-related comorbidities, but it can reduce BMD by 1 to 2% over one to two years. This is often considered clinically acceptable, as the metabolic benefits outweigh the small bone loss. However, postmenopausal women already have increased fracture risk, so even modest BMD declines could be concerning. Semaglutide induces significant weight loss, typically 10 to 15% of body weight, which is greater than older GLP-1 drugs.
The 2023 Russian investigation suggests that semaglutide-associated BMD changes are similar to those seen with lifestyle-induced weight loss. This implies no unique skeletal toxicity. Yet, long-term fracture data are scarce. The Danish registry study provides some reassurance, but follow-up was only two years. Osteoporotic fractures often occur later, so extended surveillance is necessary.
Clinicians may consider monitoring BMD in high-risk women on semaglutide, especially those with prior fractures or very low baseline BMD. Calcium and vitamin D supplementation, along with weight-bearing exercise, could help preserve bone during treatment. Cardiovascular safety of semaglutide in women is another important aspect, as heart health and bone health are interconnected in aging populations.
Common questions
Does semaglutide cause bone loss in postmenopausal women?
Current evidence does not show significant bone loss beyond what is expected from weight reduction. A 2023 investigation found only small, non-significant BMD decreases in semaglutide users. Transient increases in bone resorption markers may occur early in treatment but appear to normalize. Long-term fracture data are limited, but a 2024 Danish study suggested no increased fracture risk and possibly a slight protective effect compared to some other diabetes drugs.
How does semaglutide compare to other GLP-1 drugs for bone health?
Most GLP-1 receptor agonists have neutral or slightly positive effects on bone in animal models. Human data are sparse. Liraglutide and exenatide have shown increases in bone formation markers in small trials. Semaglutide has not been directly compared to them in bone-specific studies. The Danish registry analysis found similar fracture rates between semaglutide and SGLT-2 inhibitors, but a lower rate versus DPP-4 inhibitors. More head-to-head trials are needed.
Can kisspeptin improve bone density during semaglutide treatment?
Kisspeptin has shown bone-protective effects in animal models, but no human trials have tested it in combination with semaglutide. The idea is theoretical. Kisspeptin primarily regulates reproductive hormones, which influence bone turnover. Combining it with a GLP-1 agonist might address both metabolic and skeletal health, but this is purely investigational. Patients should not use kisspeptin for bone health outside of clinical trials.
What should postmenopausal women on semaglutide do to protect their bones?
Standard bone health measures are recommended: adequate calcium and vitamin D intake, regular weight-bearing and resistance exercise, and avoidance of smoking and excessive alcohol. BMD testing may be considered for women at high fracture risk. There is no evidence that semaglutide requires specific bone monitoring beyond usual care. Any concerns should be discussed with a healthcare provider, especially if other osteoporosis risk factors are present.